Jerlyn K Sponseller1, Jennifer A Steele1, Diane J Schmidt1, Hyeun Bum Kim2, Gillian Beamer1, Xingmin Sun1, Saul Tzipori1. 1. Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts. 2. Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts Department of Animal Resources Science, Dankook University, Cheonan, Choongnam, Republic of Korea.
Abstract
BACKGROUND: Clostridium difficile is a primary cause of antibiotic-associated diarrhea that typically develops when gut microbiota is altered. Conventional treatment for C. difficile infection (CDI) is additional antimicrobial administration, which further disrupts normal intestinal microbiota, often resulting in poor treatment outcomes. METHODS: A pregnant dairy cow was repeatedly immunized with recombinant mutants of toxins A and B produced by C. difficile, and the resultant hyperimmune bovine colostrum (HBC) was evaluated for therapeutic efficacy in gnotobiotic piglets with diarrhea due to CDI. Control piglets received nonimmune colostrum. To determine the impact of HBC on gut microbiota, 1 of 2 groups of piglets transplanted with normal human gut microbiota was treated with HBC. RESULTS: Nonimmune colostrum-treated piglets developed moderate to severe diarrhea and colitis. In contrast, HBC-treated piglets had mild or no diarrhea and mild or no colitis. Lyophilization had no detectable impact on HBC efficacy. HBC had no discernible effect on the composition of normal human gut microbiota in the porcine intestinal tract. CONCLUSIONS: HBC provides an oral, cost-effective, and safe alternative to antibiotic therapy for CDI. By preserving intestinal microbiota, HBC may be more efficacious than antibiotics. Additional studies are warranted to establish HBC as a viable immunotherapeutic agent for human use against CDI.
BACKGROUND:Clostridium difficile is a primary cause of antibiotic-associated diarrhea that typically develops when gut microbiota is altered. Conventional treatment for C. difficileinfection (CDI) is additional antimicrobial administration, which further disrupts normal intestinal microbiota, often resulting in poor treatment outcomes. METHODS: A pregnant dairy cow was repeatedly immunized with recombinant mutants of toxins A and B produced by C. difficile, and the resultant hyperimmune bovine colostrum (HBC) was evaluated for therapeutic efficacy in gnotobiotic piglets with diarrhea due to CDI. Control piglets received nonimmune colostrum. To determine the impact of HBC on gut microbiota, 1 of 2 groups of piglets transplanted with normal human gut microbiota was treated with HBC. RESULTS: Nonimmune colostrum-treated piglets developed moderate to severe diarrhea and colitis. In contrast, HBC-treated piglets had mild or no diarrhea and mild or no colitis. Lyophilization had no detectable impact on HBC efficacy. HBC had no discernible effect on the composition of normal human gut microbiota in the porcine intestinal tract. CONCLUSIONS:HBC provides an oral, cost-effective, and safe alternative to antibiotic therapy for CDI. By preserving intestinal microbiota, HBC may be more efficacious than antibiotics. Additional studies are warranted to establish HBC as a viable immunotherapeutic agent for human use against CDI.
Authors: R J Playford; C E MacDonald; D P Calnan; D N Floyd; T Podas; W Johnson; A C Wicks; O Bashir; T Marchbank Journal: Clin Sci (Lond) Date: 2001-06 Impact factor: 6.124
Authors: C P Kelly; S Chetham; S Keates; E F Bostwick; A M Roush; I Castagliuolo; J T LaMont; C Pothoulakis Journal: Antimicrob Agents Chemother Date: 1997-02 Impact factor: 5.191
Authors: Aron J Hall; Aaron T Curns; L Clifford McDonald; Umesh D Parashar; Ben A Lopman Journal: Clin Infect Dis Date: 2012-04-04 Impact factor: 9.079
Authors: Eero Mattila; Veli-Jukka Anttila; Markku Broas; Harri Marttila; Paula Poukka; Kaisa Kuusisto; Liana Pusa; Kari Sammalkorpi; Jan Dabek; Olli-Pekka Koivurova; Markku Vähätalo; Veikko Moilanen; Tom Widenius Journal: Scand J Infect Dis Date: 2008
Authors: Z Khan; C Macdonald; A C Wicks; M P Holt; D Floyd; S Ghosh; N A Wright; R J Playford Journal: Aliment Pharmacol Ther Date: 2002-11 Impact factor: 8.171
Authors: Benjamin W Jester; Hui Zhao; Mesfin Gewe; Thomas Adame; Lisa Perruzza; David T Bolick; Jan Agosti; Nhi Khuong; Rolf Kuestner; Caitlin Gamble; Kendra Cruickshank; Jeremy Ferrara; Rachelle Lim; Troy Paddock; Colin Brady; Stacey Ertel; Miaohua Zhang; Alex Pollock; Jamie Lee; Jian Xiong; Michael Tasch; Tracy Saveria; David Doughty; Jacob Marshall; Damian Carrieri; Lauren Goetsch; Jason Dang; Nathaniel Sanjaya; David Fletcher; Anissa Martinez; Bryce Kadis; Kristjan Sigmar; Esha Afreen; Tammy Nguyen; Amanda Randolph; Alexandria Taber; Ashley Krzeszowski; Brittney Robinett; David B Volkin; Fabio Grassi; Richard Guerrant; Ryo Takeuchi; Brian Finrow; Craig Behnke; James Roberts Journal: Nat Biotechnol Date: 2022-03-21 Impact factor: 68.164
Authors: Diane J Schmidt; Gillian Beamer; Jacqueline M Tremblay; Jennifer A Steele; Hyeun Bum Kim; Yaunkai Wang; Michele Debatis; Xingmin Sun; Elena A Kashentseva; Igor P Dmitriev; David T Curiel; Charles B Shoemaker; Saul Tzipori Journal: Clin Vaccine Immunol Date: 2016-09-06
Authors: Melanie L Hutton; Bliss A Cunningham; Kate E Mackin; Shelley A Lyon; Meagan L James; Julian I Rood; Dena Lyras Journal: Sci Rep Date: 2017-06-16 Impact factor: 4.379